Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients
Colom-Fernández, B. (Instituto de Investigación Hospital Universitario de la Princesa)
Kreutzman, A. (Instituto de Investigación Hospital Universitario de la Princesa)
Marcos-Jiménez, A. (Instituto de Investigación Hospital Universitario de la Princesa)
Garcia-Gutierrez, Valentin (Hospital Universitario Ramón y Cajal (Madrid))
Cuesta-Mateos, C. (Instituto de Investigación Hospital Universitario de la Princesa)
Portero-Sainz, I. (Instituto de Investigación Hospital Universitario de la Princesa)
Pérez-García, Yaiza (Instituto de Investigación Hospital Universitario de la Princesa)
Casado Montero, Luis Felipe (Hospital Virgen de la Salud (Toledo))
Sánchez-Guijo, F. (Instituto de Investigación Biomédica de Salamanca)
Martínez-López, J. (Hospital Universitario 12 de Octubre (Madrid))
Ayala, Rosa (Hospital Universitario 12 de Octubre (Madrid))
Boque, Concepcion (Institut Català d'Oncologia)
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Montero, I. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Soto, C. (Hospital Povisa (Vigo, Pontevedra))
Paz, R. (Hospital Universitario La Paz (Madrid))
Silva, G. (Instituto de Investigación Hospital Universitario de la Princesa)
Vega-Piris, L. (Instituto de Investigación Hospital Universitario de la Princesa)
Steegmann, J. L. (Instituto de Investigación Hospital Universitario de la Princesa)
Muñoz Calleja, Cecilia (Instituto de Investigación Hospital Universitario de la Princesa)
Universitat Autònoma de Barcelona

Fecha:	2019
Resumen:	Introduction: Dasatinib is a dual SRC/ABL tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is known to have unique immunomodulatory effects. In particular, dasatinib intake typically causes lymphocytosis, which has been linked to better clinical response. Since the underlying mechanisms are unknown and SRC family kinases are involved in many cell motility processes, we hypothesized that the movement and migration of lymphocytes is modulated by dasatinib. Patients, Materials and Methods: Peripheral blood samples from CML patients treated with second-line dasatinib were collected before and 2 h after the first dasatinib intake, and follow-up samples from the same patients 3 and 6 months after the start of therapy. The migratory capacity and phenotype of lymphocytes and differential blood counts before and after drug intake were compared for all study time-points. Results: We report here for the first time that dasatinib intake is associated with inhibition of peripheral blood T-cell migration toward the homeostatic chemokines CCL19 and CCL21, which control the trafficking toward secondary lymphoid organs, mainly the lymph nodes. Accordingly, the proportion of lymphocytes in blood expressing CCR7, the chemokine receptor for both CCL19 and CCL21, decreased after the intake including both naïve CD45RA+ and central memory CD45RO+ T-cells. Similarly, naïve B-cells diminished with dasatinib. Finally, such changes in the migratory patterns did not occur in those patients whose lymphocyte counts remained unchanged after taking the drug. Discussion: We, therefore, conclude that lymphocytosis induced by dasatinib reflects a pronounced redistribution of naïve and memory populations of all lymphocyte subsets including CD4+ and CD8+ T-cells and B-cells.
Ayudas:	Instituto de Salud Carlos III PI18-01163
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	CCR7 ; Dasatinib ; Chronic myeloid leukemia ; Lymphocytosis ; Migration
Publicado en:	Frontiers in Pharmacology, Vol. 10 (2019) , p. 1340, ISSN 1663-9812

DOI: 10.3389/fphar.2019.01340
PMID: 31824308

11 p, 2.0 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Instituto de Investigación contra la Leucemia Josep Carreras
Artículos > Artículos de investigación
Artículos > Artículos publicados